Agonist
Back to library
AestheticSubcutaneous

PT-141

Also known as: Bremelanotide · Vyleesi

MC4R-selective melanocortin receptor agonist. Acts on hypothalamic circuits to increase sexual arousal independent of vascular pathways. FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.

At a glance

Half-life
2.7 hours
Common route
Subcutaneous
Typical dose range
750–2,000mcg
Stability (reconstituted)
30days refrigerated

Best timing

On-demand, 45 minutes to 2 hours before activity. Avoid more than once every 24 hours; max 8 doses per month per label.

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy
  • Concurrent naltrexone (efficacy reduction)

Watch symptoms

  • Nausea (most common — pre-medicate with anti-emetic if persistent)
  • Facial flushing
  • Transient blood pressure elevation
  • Headache
  • Focal hyperpigmentation on face or gums with repeated dosing

Citations

The primary literature.

  1. 01Bremelanotide for hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT)PubMed
  2. 02Bremelanotide: a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorderPubMed
Back to library